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Abstract 
Background: Multimorbidity in allergic airway diseases is well known, but no data exist about the 
daily dynamics of symptoms and their impact on work. To better understand this, we aimed to assess 
the presence and control of daily allergic multimorbidity (asthma, conjunctivitis, rhinitis) and its 
impact on work productivity using a mobile technology, the Allergy Diary, 
Methods: We undertook a one year prospective observational study in which 4,210 users and 32,585 
days were monitored in 19 countries. Five visual analogue scales (VAS) assessed the daily burden of 
the disease (i.e. global evaluation, nose, eyes, asthma and work). VAS levels <20/100 were 
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Results: VAS global measured levels assessing the global control of the allergic disease were 
significantly  associated with allergic multimorbidity. Eight hypothesis-driven patterns were defined 
based on “Low” and “High” VAS levels. There were <0.2% days of Rhinitis Low and Asthma High 
or Conjunctivitis High patterns. There were 5.9% days with a Rhinitis High - Asthma Low pattern. 
There were 1.7% days with a Rhinitis High – Asthma High – Conjunctivitis Low pattern. A novel 
Rhinitis High - Asthma High - Conjunctivitis High pattern was identified in 2.9% days and had the 
greatest impact on uncontrolled VAS global measured and impaired work productivity. Work 
productivity was significantly correlated with VAS global measured levels. 
Conclusions: In a novel approach examining daily symptoms with mobile technology we found 
considerable intra-individual variability of allergic multimorbidity including a previously 
unrecognized extreme pattern of uncontrolled multimorbidity. 
 




AR: allergic rhinitis 
ARIA: Allergic Rhinitis and its Impact on Asthma 
ICT: information and communications technology 
MACVIA: Contre les MAladies Chroniques pour un VIeillissement Actif  
MASK: MACVIA-ARIA Sentinel NetworK 
MeDALL: Mechanisms of the Development of Allergy (FP7) 
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Allergic diseases are complex and often cluster resulting in multimorbidity 1. It is estimated that the 
vast majority of patients with asthma have rhinitis. Conversely, around 20-40% of patients with 
allergic rhinitis (AR) experience bronchial symptoms 1-3 irrespective of the allergic sensitization 4. 
There are several unmet needs in the understanding of the relationship between upper and lower 
airways pathophysiology 2,5,6. In particular, the stated prevalence of nasal, bronchial and ocular 
symptoms in AR varies widely between studies. In some clinical trials with patients suffering from 
moderate to severe asthma, the vast majority of patients also have rhinitis multimorbidity. Eye 
symptoms have been largely studied in rhinitis and asthma 1-3,7,8 and often represent the most severe 
AR symptoms 9-11. However, there is little information concerning the impact of eye symptoms on 
global disease severity or control, or their association with the asthma-rhinitis multimorbidity. No 
study has assessed multimorbidity on a daily basis whereas environmental exposure varies widely 
between days.  
Two approaches can be proposed to assess multimorbidity. In MeDALL (Mechanisms of the 
Development of Allergy, FP7)12,13, both hypothesis-driven 14 and data-driven approaches with 
machine learning tools 15,16 were used.  However, so far, previous studies have not considered the 
daily joint co-occurrence of multimorbidity symptoms.   
MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) is a patient centred ICT 
(information and communication technologies) system 17,18. A mobile phone app (Allergy Diary) 
central to MASK is available in 22 countries. It has been validated 19 and was found to be an easy and 
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In order to better understand daily allergic multimorbid patterns, the Allergy Diary was used over a 
one-year period assessing days instead of patients.  
 
Methods 
Design of the study 
An observational study was carried out on all users who filled in the Allergy Diary from May, 25, 
2016 to May 24, 2017. Five visual analogue scales (VAS) assessed the daily control of the disease 
(i.e. global evaluation of allergic symptoms, nose, eye, asthma and work productivity) 20. The primary 
objective of the study was to assess prevalence and control of the daily allergic multimorbidity 
(asthma, conjunctivitis, rhinitis) according to recorded daily overall control (global evaluation). 
Secondary objectives included the impact of multimorbidity on work and the characterization of 
multimorbid patterns. In this study, a hypothesis-driven approach was used to select groups depending 
on VAS levels (high level: VAS≥50/100, low level: VAS < 20/100) 12. 
The paper was written according to the STROBE checklist. 
Setting   
Users from 19 countries filled in the Allergy Diary (Table 1). The three countries with under 25 users 
were excluded from the analysis (i.e. Canada, Czech Republic and Turkey). The Allergy Diary is 
available in 16 languages (translated and back-translated, culturally adapted and legally compliant). 
Users  
All consecutive users who registered to the Allergy Diary were included if they had filled in the VAS 
global measured. The first question of the Allergy Diary is “do you have allergic rhinitis (Yes, No)?” 
There were no exclusion criteria. Some demographic characteristics (age, sex, country and language) 
were recorded. The Allergy Diary was used by people who found it on the internet, Apple store, 
Google Play or in any other way. Some users were clinic patients who were asked by their physicians 
to use the app. However, due to anonymization of data, no specific information could be gathered as 
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Allergy Diary and outcomes 
The app collects information on AR symptoms experienced on a specific day. Geolocalized users 
assess their daily symptom control via the touchscreen functionality on their smart phone:  they click 
on 5 consecutive VAS measures (VAS-global measured, VAS-nasal, VAS-ocular, VAS-asthma and 
VAS-work). Levels range from zero (not at all bothersome) to 100 (very bothersome). Independency 
of VAS questions was previously assessed using the Bland and Altman regression analysis 22,24. 
Some of the VAS data used in this study have been analyzed in other studies with a different aim 
including work productivity 21 and assessment of treatment (paper in press). Moreover, the time frame 
of the two other studies was different. 
 
Ethics 
The Allergy Diary is CE1 registered. However, it is not considered by the Ethical Committee of the 
Cologne Hospital or the MHRA (Medicines and Healthcare products Regulatory Agency - GOV.UK) 
as a medical device as it does not give any recommendations concerning treatment or diagnosis. The 
terms of use have been translated into all languages and customized according to the legislation of 
each country. This thereby allows the use of the results for research purposes.  The data are 
anonymized except for the geolocalized data that are never totally anonymous 21,22. An Independent 
Review Board approval was not needed for this observational study. 
 
Biases 
As for all studies using big data, there are biaises which should be considered. These include sampling 
bias likely present, difficult to assess generalizability of the study, outcome misclassification cannot be 
assessed and, by definition due to ethical problems, there very little information on patient (or day) 
characteristics.  
In the database, 1,860 users have filled in the VAS for over a week. Thus, the analysis of days that 
correspond to repeated observations for the same individuals is likely to have inflated the correlation 
between the different types of VAS. In a previous study, it was found that the correlation between 
VAS global measured and VAS nose increased from Rho=0.76 for day 1 to Rho=0.83 for all days21. 
Moreover, this was also confirmed in the validation study 19 
For this study, other biases should be considered. The diagnosis of AR was not supported by a 
physician but was a response to the question: “Do you have allergic rhinitis? Yes/No”. There may 










This article is protected by copyright. All rights reserved. 
treatments are not considered since there is a need for a combined symptom-medication score that is 
currently being developed. However, it was found that the level  of  control of allergic symptoms 
(asthma or rhinitis) was independent of treatment 25,26 making it possible to analyze the data.     
 
Size of the study 
In this exploratory pilot study, all registered users over the one-year study period were included to 
obtain the best possible estimates for the specified time window.    
 
Statistical analysis 
Some of the data did not follow a Gaussian distribution. Medians and percentiles as well as non-
parametric tests were used for data following a non-Gaussian distribution. The statistically significant 
correlations were ascribed to “very strong” (Rho ranging from 0.80 to 1.00), “strong” (Rho ranging 
from 0.60 to 0.79) or “moderate” (Rho ranging from 0.40 to 0.59) 21. We then assessed allergic 




From May 24, 2016 to May 25, 2017, a total of 4,210 users from 19 countries filled in the VAS 
(Table 1). They ranged in age from 12 to 92 years (mean ± SD: 39 ±16.5 years). There were 2,169 
females (51.5%) and 2,041 males (48.5%). 1,860 users filled in the VAS once only, 1,517 from 2 to 7 
days, 349 from 8 to 15 days and 484 filled it in for over 16 days (up to 365 days). Less than 10% of 
users were over 60 years and we did not stratify the study by age. 
 
Overall results 
32,585 days were recorded for VAS global measured, nose and eyes, but only 32,095 (98.5%) days 
for VAS asthma (due to a delay in translations in some of the countries) and 17,505 (53.1%) days for 
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Median VAS levels all increased similarly with the increasing level of VAS global measured although 
VAS nose levels are higher than the others (Table 2).   
There were 7,052 (21.6%) days with a measurement of zero for VAS global measured and 18,488 for 
asthma (Tables 1 online). The prevalence of days with VAS ≥1 decreased from VAS nose to VAS 
work, VAS eye and VAS asthma (Figure 1). Over 80% days with VAS global measurement ≥50 had a 
detectable VAS eye. On the other hand, up to 62% of days with VAS global measurement ≥50 had a 
detectable VAS asthma. For days with VAS level ≥ 1, median levels of VAS increased with the 
global severity of the day and were similar for asthma, eye and work (Figure 1).  
Using the Spearman rank correlation for the entire database, we found significant correlations 
between all VAS levels (Table 1 online, Figure 1 online): 
• A very strong correlation was found between VAS global measurement and nose (Rho > 0.88) or 
work (Rho > 0.82),  
• A strong correlation was found between VAS global measurement and eye (Rho > 0.71), VAS 
nose and eye (Rho > 0.63) or work (Rho > 0.77), VAS eye and work (Rho > 0.69) and VAS 
asthma and work (Rho > 0.60). 
• A moderate correlation was found between VAS asthma and global measurement (Rho > 0.55), 
nose (Rho > 0.50) and eye (Rho > 0.52). 
Patterns of daily multimorbidity of allergic rhinitis 
We studied four asthma-nose or eye-nose distinct patterns according to the consensus on VAS 
control: 0-19 (Low: well controlled), 20-49 (partly controlled) and ≥50 (High: uncontrolled) (Figure 
2).  
There were very few days (<0.5%) with High Asthma or High Conjunctivitis and Low Rhinitis. There 
were also few days (<0.5 %) with low asthma or low conjunctivitis and high rhinitis.  
The correlation between VAS eye and asthma is moderate (Rho=0.53) (Figure 2 online).  
Daily Asthma-Rhinitis patterns were dependent on VAS global measured (Figure 3). The same trends 
were found for the Conjunctivitis-Rhinitis patterns. 
• Asthma Low (<20) - Rhinitis Low (<20): This pattern was mainly found for VAS global 
measured levels <20 and at a lesser extend for VAS <50. 
• Asthma High (≥50) - Rhinitis Low (<20): This pattern was extremely rare (<0.5%) for all VAS 
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• Asthma Low (<20) - Rhinitis High (≥50): This pattern was extremely rare in VAS global 
measured levels <20 (< 0.5%), was rare for 20-49 and was frequent for levels ≥50. 
• Asthma High (≥50) - Rhinitis High (≥50): This pattern was almost exclusively found in VAS 
global measured levels ≥50. 
There was a very large number of zero values (N=13,915 for VAS eye and N=18,488 for VAS 
asthma). There are 1.8% days with an Asthma High-Conjunctivitis Low pattern and 5.2% days with 
Asthma Low-Conjunctivitis High pattern. 
The same trends were found for the Conjunctivitis-Rhinitis patterns. Slightly over 14% days had a 
VAS nose ≥ 50 (Rhinitis High) (Table 3). Among them, four groups were identified: (i) Asthma Low 
and Conjunctivitis Low, (ii) Asthma Low and Conjunctivitis High, (iii) Asthma High and 
Conjunctivitis Low and (iv) the extreme pattern: Asthma High and Conjunctivitis High. The levels of 
VAS global and work increased significantly between the four patterns. In the extreme pattern (Nose, 
eye and asthma High), there was an increased VAS level of all five criteria. The yearly repartition of 
uncontrolled rhinitis, conjunctivitis and asthma indicates that there is an over-representation of days in 
March, April, May and June (Figure 3 online). However, these patterns were observed for all other 
months. 
In order to assess whether reporting VAS levels on day 1 may affect the results, we studied 1,060 
users who reported at least one day of rhinitis VAS ≥50 and over two days of VAS: 145 (13.7%) had 
a VAS ≥50 on day 1 only, 498 (47%) had a VAS ≥50 on day 1 and another day, and 417 (39.3%) had 
a VAS <50 on day 1 and ≥50 another day. 
 
Discussion  
This observational study is, to our knowledge, the first to examine daily patterns of allergic 
multimorbidity and work productivity in patients with allergic rhinitis. The mobile technology 
facilitates an innovative investigatory approach to better and more precisely characterize allergic 
multimorbidity. It provides novel insights in allergic multimorbidity. VAS global measured levels 
determine allergic multimorbidity. Four hypothesis-driven patterns were defined. In the population 
filling in the App (AR sufferers), there were hardly no Asthma High-Rhinitis Low or Conjunctivitis 
High-Rhinitis Low patterns. On the other hand, there were many days with Rhinitis High without 
asthma. The Asthma High-Rhinitis High and Conjunctivitis High-Rhinitis High (VAS global 
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pattern. Work productivity was strongly correlated with VAS global measured levels, and also with 
the multimorbid patterns. 
Strengths and limitations  
There are potential measurement biases when using apps since the information collected is usually 
restricted and less complete than when using more detailled paper or web-based questionnaires. A 
bias might be introduced given that app users may be a selected subset and therefore not fully 
representative of all patients with rhinitis. Higher education or specific age ranges might apply. The 
study was not meant to be representative of the general population.  The strengths and limitations of 
this study are those of mobile technology, as previously discussed 21,22.  Precise patient 
characterization is impossible using an App, but every observational study using the Allergy Diary 
was able to identify days with poor control or criteria of severity 19,21-23. Mobile technology is likely to 
become an important tool to better understand and manage AR and asthma. 
Smart devices and internet-based applications are already used in rhinitis but none have assessed 
allergic multimorbidity using days. This can be easily approached using the Allergy Diary. The 
strengths of the mobile technology include its wide acceptance and easy use, but there is a need to use 
appropriate questions, and results should be assessed by studies. This study was based on 4,210 users 
who filled in 32,585 days of VAS to answer some of the questions not yet studied 19,21-23. 
Asthma was assessed using a single VAS largely validated in rhinitis 20. In asthma, VAS was shown 
to be an effective measure of control 28. In the present study, we did not investigate specific symptoms 
or perform any pulmonary function test. Thus, it is possible that some users may have misunderstood 
the question or overestimated the disease. However, the results are extremely consistent.  
Stratification by age or sex has not been performed because in this study we considered days and not 
patients. This will be done at a later stage with a greater population. 
We only considered days and not patients’ trajectories because these are highly variable, patients 
using auto-medication depending on AR control (paper in preparation), and we need to develop a 
symptom-medication score (in preparation).  
Generalizability 
The results found a very low number of days of uncontrolled asthma or conjunctivitis without rhinitis. 
However, there may be a selection bias (users with AR using the App) and these results should be 
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The VAS nose has a major impact on the VAS global assessment of multimorbidities as it is more 
closely associated with it than VAS eyes or VAS asthma.  
Asthma-rhinitis multimorbidity is well known 29 but the present study has added three novel findings: 
(i) Three uncontrolled patterns were found depending on VAS nose, eye and asthma. Rhinitis appears 
to be driving the overall loss of control of the disease but asthma and conjunctivitis are each adding 
some impact demonstrated by VAS global measured and VAS work. (ii) This study enabled a better 
appreciation of conjunctivitis multimorbidity.  (iii) A novel extreme pattern of uncontrolled disease is 
associated with nose, eye and asthma multimorbidity. Interestingly, this extreme pattern was 
identified in MeDALL (Mechanisms of the Development of Allergy, FP7)13,14 but not considered. In 
the hypothesis-driven analysis we combined rhinoconjunctivitis in the same multimorbidity analysis 
14. However, the data-driven cluster analysis showed that ocular symptoms were observed 15 
confirming the results of the present study. New analyses will be done thanks to the results of the 
current study that stresses the importance of combining big data using undefined users and more 
classical epidemiological approaches. This phenotype was also identified in the EGEA study in which 
the prevalence of conjunctivitis is the highest in the asthma-rhinitis phenotype, but, again, not 
sufficiently considered.28 These data strongly support the holistic and multidisciplinary approach of 
“one airway one disease” for the management of allergic airway diseases 29,30. Although there is an 
increased number of days during the pollen season (March, April, May and June), there is a need to 
individually assess allergen exposure and pollution data to better understand the links between the 
nose, the eyes and the lower airways. This is the Horizon 2020 proposal POLLAR (Impact of air 
Pollution in asthma and rhinitis) recently funded. 
Work impairment is confirmed in the present study. It extends the findings from our previous study 
with 5,600 days 21 as (i) the same levels of correlation between VAS work and VAS global measured, 
nose, eye or asthma were found in a larger population (17,505 days). (ii) According to correlations, 
the  multimorbid pattern (VAS global measured) is the most closely associated with VAS work,  
followed by nose, eye and asthma. (iii) However, when comparing Rhinitis High phenotypic days, the 
levels of VAS work increased from a median of 37 (Asthma Low, Conjunctivitis Low), to 64 (Asthma 
High, Conjunctivitis High) showing the major impact of multimorbidity in work productivity. (iv) 
Finally, the study shows that, even in days with mild global symptoms, there is an impairment of 
work productivity confirming a recent study of the baseline characteristics of Allergy Diary using the 
Work-Productivity and Activity Questionnaire (WPAI-AS) 31. 
The existence of different patterns of daily multimorbidity in people with rhinitis should be confirmed 
in a study combining individuals and days in the same analysis and using a cluster analysis and in 
general population and patient’s cohorts with well-defined phenotypes. If confirmed, the results of the 
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propose “change management” 32 for rhinitis, asthma and conjunctivitis multimorbidity. For novel 
care pathways, we should consider both days and patients and not only patients. This approach would 
be helpful to patients as well as payers in concentrating resources on the most symptomatic days and 
where improvement would result in most effect personally and societal. The concept observed in this 
study may be expanded to other chronic diseases 31. 
Conclusion 
The present paper is a novel and intuitive way of presenting daily patterns of multimorbidity and 
stratifying risk of allergic rhinitis.  
This analysis also suggests that big data that are soon coming to allergic diseases should be 
considered differently than the classical approach. They will complement our current knowledge, with 
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Table 1: Repartition of users  
Country Number of users Country Number of users 
Austria 256 Lithuania 137 
Australia 32 Mexico 197 
Belgium 57 Netherlands 135 
Brazil 205 Poland 230 
Denmark 36 Portugal 866 
Finland 225 Spain 258 
France 420 Sweden 58 
Germany 305 Switzerland 80 
Greece 82 UK 117 
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Table 2: Overall results 
VAS Global N (days) Nose Eye Asthma Work 
0 7052 0 (0-0) 0 (0-0) 0 (0-1) N=3260 0 (0-1) 
1-9 6676 6 (3-10) 1 (0-6) 0 (0-4) N=3820 2 (0-6)
10-19 5635 15 (10-20) 6 (0-15) 0 (2-20) N=2623 10 (5-15) 
20-29 3481 24 (18-31) 14 (0-25) 0 (2-20) N=2001 18 (9-25) 
30-39 2290 36 (26-42) 19 (1-35) 4 (0-28) N=1219 24 (14-34) 
40-49 1888 46 (36-53) 28 (6-47) 6 (0-33) N=995 34 (20-45) 
50-59 1682 53 (47-61) 39 (12-54) 10 (0-50) N=966 44 (27-53) 
60-69 1235 64 (54-71) 45 (16-65) 13 (0-54) N=690 51 (36-61) 
70-79 933 74 (62-80) 52 (21-74) 22 (0-26) N=547 56 (39-68) 
80-89 570 81 (71-87) 61 (23-83) 28 (0-78) N=294 65 (47-77) 
90-99 409 91 (79-96) 78 (45-94) 54 (5-92) N=213 69 (52-85) 
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N 1372 (4.2%) 1724 (5.3%) 520 (1.5%) 1039 (3.2%)   
VAS global 53 (44-67) 62 (51-75) 68 (55-82) 74 (59-88) A/B, A/C, A/D, B/C, B/D, C/D 
VAS nose 63 (54-77) 67 (57-79) 66 (58-78) 74 (61-88) C/D   
VAS eye 1 (0-9) 51 (35-68) 23 (6-37) 73 (59-85) B/D (other comparisons not appriate) 
VAS asthma 0 (0-2) 0 (0-5) 65 (56-77) 73 (60-86) C/D (other comparisons not appriate)  
VAS Work (N) 667 714 266 475   
VAS work 37 (16-53) 49 (30-61) 54 (36-51) 64 (53-77) A/B, A/C, A/D, B/C, B/D, C/D 










Figure 1: Relationship between VAS Glo
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Figure 3: Daily asthma and rhinitis patte
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